Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression

Liver International

Volumn 29, Issue 7, 2009, Pages 1031-1042

  Fava, Giammarco ^a   Demorrow, Sharon ^a,b   Gaudio, Eugenio ^c   Franchitto, Antonio ^c   Onori, Paolo ^d   Carpino, Guido ^e   Glaser, Shannon ^a,b   Francis, Heather ^a,b,f   Coufal, Monique ^f   Marucci, Luca ^a   Alvaro, Domenico ^c   Marzioni, Marco ^a   Horst, Trenton ^a   Mancinelli, Romina ^a,c   Benedetti, Antonio ^a   Alpini, Gianfranco ^a,b,g  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF L'AQUILA   (Italy)

^e UNIVERSITY OF ROME FORO ITALICO   (Italy)

^f Division of Research and Education   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Biliary cancer; Cholangiopathies; Neuroendocrine hormones; Proliferation; Vascular endothelial growth factor

Indexed keywords

COLLAGEN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROTEIN CONTENT; TUMOR VOLUME;

ANIMALS; APOPTOSIS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL LINE, TUMOR; CELL PROLIFERATION; CHOLANGIOCARCINOMA; COLLAGEN; DOWN-REGULATION; ENDOTHELIN-1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RNA, MESSENGER; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 67650495396     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2009.01997.x     Document Type: Article

References (60)

1. Gores GJ. Cholangiocarcinoma: Current concepts and insights. Hepatology 2003; 37: 961-9.
2. Blechacz B, Gores GJ. Tumor-specific marker genes for intrahepatic cholangiocarcinoma: Utility and mechanistic insight. J Hepatol 2008; 49: 160-2.
3. Blechacz BR, Gores GJ. Cholangiocarcinoma. Clin Liver Dis 2008; 12: 131-50, ix.
4. Sirica AE. Cholangiocarcinoma: Molecular targeting strategies for chemoprevention and therapy. Hepatology 2005; 41: 5-15.
5. Fava G, Marucci L, Glaser S, et al. Gamma-aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. Cancer Res 2005; 65: 11437-46.
6. Werneburg NW, Yoon JH, Higuchi H, Gores GJ. Bile acids activate EGF receptor via a TGF-alpha-dependent mechanism in human cholangiocyte cell lines. Am J Physiol Gastrointest Liver Physiol 2003; 285: G31-6.
7. Fava G, Alpini G, Rychlicki C, et al. Leptin enhances cholangiocarcinoma cell growth. Cancer Res 2008; 68: 6752-61.
8. Tan CK, Podila PV, Taylor JE, et al. Human cholangiocarcinomas express somatostatin receptors and respond to somatostatin with growth inhibition. Gastroenterology 1995; 108: 1908-16.
9. Marzioni M, Fava G, Benedetti A. Nervous and neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World J Gastroenterol 2006; 12: 3471-80.
10. 2+ -dependent protein kinase C-alpha. J Hepatol 2001; 34: 284-91.
11. Kanno N, Lesage G, Phinizy JL, et al. Stimulation of alpha2-adrenergic receptor inhibits cholangiocarcinoma growth through modulation of Raf-1 and B-Raf activities. Hepatology 2002; 35: 1329-40.
12. Alvaro D, Mancino MG, Onori P, et al. Estrogens and the pathophysiology of the biliary tree. World J Gastroenterol 2006; 12: 3537-45.
13. Demorrow S, Glaser S, Francis H, et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: Recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007; 282: 13098-113.
14. Tostes RC, Fortes ZB, Callera GE, et al. Endothelin, sex and hypertension. Clin Sci 2008; 114: 85-97.
15. Caligiuri A, Glaser S, Rodgers RE, et al. Endothelin-1 inhibits secretin-stimulated ductal secretion by interacting with ET A receptors on large cholangiocytes. Am J Physiol Gastrointest Liver Physiol 1998; 275: G835-46.
16. Housset C, Carayon A, Housset B, et al. Endothelin-1 secretion by human gallbladder epithelial cells in primary culture. Lab Invest 1993; 69: 750-5.
17. Iwasaki S, Homma T, Matsuda Y, Kon V. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem 1995; 270: 6997-7003.
18. Pinzani M, Milani S, de Franco R, et al. Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells. Gastroenterology 1996; 110: 534-48.
19. Luo B, Tang L, Wang Z, et al. Cholangiocyte endothelin 1 and transforming growth factor beta1 production in rat experimental hepatopulmonary syndrome. Gastroenterology 2005; 129: 682-95.
20. 2+)-, and protein kinase C alpha-dependent mechanisms. Hepatology 2000; 32: 17-25.
21. Francis H, Glaser S, Ueno Y, et al. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol 2004; 41: 528-37.
22. Ogasawara S, Yano H, Higaki K, et al. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 2001; 20: 97-113.
23. Benckert C, Jonas S, Cramer T, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63: 1083-92.
24. Mancino A, Mancino MG, Glaser S, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis 2008; 41: 156-63.
25. Gaudio E, Barbaro B, Alvaro D, et al. Administration of r-VEGF-A prevents hepatic artery ligation-induced bile duct damage in bile duct ligated rats. Am J Physiol Gastrointest Liver Physiol 2006; 291: G307-17.
26. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130: 1270-82.
27. Gaudio E, Onori P, Pannarale L, Alvaro D. Hepatic microcirculation and peribiliary plexus in experimental biliary cirrhosis: A morphological study. Gastroenterology 1996; 111: 1118-24.
28. 2+-, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol 2004; 286: G973-82.
29. Isomoto H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007; 132: 384-96.
30. Pietersen AM, Rutjes SA, van Tongeren J, et al. The tumor-selective viral protein apoptin effectively kills human biliary tract cancer cells. J Mol Med 2004; 82: 56-63.
31. Knuth A, Gabbert H, Dippold W, et al. Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. J Hepatol 1985; 1: 579-96.
32. Demorrow S, Francis H, Gaudio E, et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/ redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol 2008; 294: G506-19.
33. Alpini G, Invernizzi P, Gaudio G, et al. Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res 2008; 68: 9184-93.
34. Seki H, Elder MG, Sullivan MH. Endothelin-1 regulates human decidual cells through both A- and B-type receptors. Mol Cell Endocrinol 1995; 114: 111-6.
35. Janosi T, Petak F, Fontao F, et al. Differential roles of Eta and Etb receptors and vasoactive intestinal peptide (Vip) in regulation of the airways and the pulmonary vasculature in isolated rat lung. Exp Physiol 2008; 93: 1210-9.
36. Gulati A, Srimal RC. Endothelin antagonizes the hypotension and potentiates the hypertension induced by clonidine. Eur J Pharmacol 1993; 230: 293-300.
37. Lesage G, Glaser S, Ueno Y, et al. Regression of cholangiocyte proliferation after cessation of ANIT feeding is coupled with increased apoptosis. Am J Physiol Gastrointest Liver Physiol 2001; 281: G182-90.
38. Veeravagu A, Hsu AR, Cai W, et al. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Pat Anticancer Drug Discovery 2007; 2: 59-71.
39. Bagnato A, Rosano L. The endothelin axis in cancer. Int J Biochem Cell Biol 2008; 40: 1443-51.
40. Fitzner B, Brock P, Holzhuter SA, et al. Synergistic growth inhibitory effects of the dual endothelin-1 receptor antagonist Bosentan on pancreatic stellate and cancer cells. Dig Dis Sci 2008; 54: 309-20.
41. Chiappori AA, Haura E, Rodriguez FA, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008; 14: 1464-9.
42. Hoosein MM, Dashwood MR, Dawas K, et al. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 775-82.
43. Watson SA, Steele RJ. Gastrin antagonists in the treatment of gastric cancer. Anticancer Drugs 1993; 4: 599-604.
44. Yassin RR, Clearfield HR, Little KM. Gastrin's trophic effect in the colon: Identification of a signaling pathway mediated by protein kinase C. Peptides 1993; 14: 1119-24.
45. Quintero E, Ohning GV, del Rivero M, et al. Gastrin mediates the increase in gastric cell growth in uremic rats. Am J Physiol Gastrointest Liver Physiol 1995; 268: G586-91.
46. Waldum HL, Brenna E, Kleveland PM, Sandvik AK. Gastrin - physiological and pathophysiological role: Clinical consequences. Dig Dis 1995; 13: 25-38.
47. Chen D, Nylander AG, Norlen P, Hakanson R. Gastrin does not stimulate growth of the rat pancreas. Scand J Gastroenterol 1996; 31: 404-10.
48. Chen D, Ding XQ, Rehfeld JF, Hakanson R. Endogenous gastrin and cholecystokinin do not promote growth of rat liver. Scan J Gastroenterol 1994; 29: 688-92.
49. Detjen K, Fenrich MC, Logsdon CD. Transfected cholecystokinin receptors mediate growth inhibition on human pancreatic cancer cell lines. Gastroenterology 1997; 112: 952-9.
50. Glaser S, Rodgers RE, Phinizy JL, et al. Gastrin inhibits secretin-induced ductal secretion by interaction with specific receptors on rat cholangiocytes. Am J Physiol Gastrointest Liver Physiol 1997; 273: G1061-70.
51. Alpini G, Lenzi R, Sarkozi L, Tavoloni N. Biliary physiology in rats with bile ductular cell hyperplasia. Evidence for a secretory function of proliferated bile ductules. J Clin Invest 1988; 81: 569-78.
52. Alpini G, Ulrich C, Roberts S, et al. Molecular and functional heterogeneity of cholangiocytes from rat liver after bile duct ligation. Am J Physiol Gastrointest Liver Physiol 1997; 272: G289-97.
53. Lesage G, Alvaro D, Benedetti A, et al. Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile duct-ligated rats. Gastroenterology 1999; 117: 191-9.
54. Lesage G, Glaser S, Gubba S, et al. Regrowth of the rat biliary tree after 70% partial hepatectomy is coupled to increased secretin-induced ductal secretion. Gastroenterology 1996; 111: 1633-44.
55. Shinkaruk S, Bayle M, Lain G, Deleris G. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. Curr Med Chem Anticancer Agents 2003; 3: 95-117.
56. Tavoloni N, Schaffner F. The intrahepatic biliary epithelium in the guinea pig: Is hepatic artery blood flow essential in maintaining its function and structure? Hepatology 1985; 55: 666-72.
57. Bell KM, Prise VE, Shaffi KM, Chaplin DJ, Tozer GM. A comparative study of tumour blood flow modification in two rat tumour systems using endothelin-1 and angiotensin II: Influence of tumour size on angiotensin II response. Int J Cancer 1996; 67: 730-8.
58. Cemazar M, Wilson I, Prise VE, et al. The endothelin B (ETB) receptor agonist IRL 1620 is highly vasoconstrictive in two syngeneic rat tumour lines: Potential for selective tumour blood flow modification. Br J Cancer 2005; 93: 98-106.
59. Krieg T, Abraham D, Lafyatis R. Fibrosis in connective tissue disease: the role of the myofibroblast and fibroblast-epithelial cell interactions. Arthritis Res Ther 2007; 9 (Suppl. 2): S4.
60. Laplante P, Raymond MA, Gagnon G, et al. Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J Immunol 2005; 174: 5740-9.